NYSEMKT:PHGE BiomX (PHGE) Stock Price, News & Analysis $0.62 +0.05 (+8.89%) (As of 12/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartFinancialsHeadlinesInsider TradesOwnershipSEC Filings About BiomX Stock (NYSEMKT:PHGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BiomX alerts:Sign Up Key Stats Today's Range$0.57▼$0.6350-Day Range$0.49▼$0.9852-Week Range N/AVolume117,757 shsAverage Volume68,601 shsMarket Capitalization$11.27 millionP/E RatioN/ADividend YieldN/APrice Target$22.50Consensus RatingBuy Company OverviewBiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Read More… BiomX Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks31st Percentile Overall ScorePHGE MarketRank™: BiomX scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiomX has received no research coverage in the past 90 days.Read more about BiomX's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PHGE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for PHGE. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for BiomX this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.01% of the stock of BiomX is held by insiders.Percentage Held by Institutions40.57% of the stock of BiomX is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BiomX's insider trading history. Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Email Address PHGE Stock News HeadlinesBiomX Inc. Regains Compliance with NYSE American Listing StandardsDecember 19 at 4:13 AM | americanbankingnews.comBiomX regains compliance with NYSE American continued listing standardsDecember 17, 2024 | markets.businessinsider.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.December 21, 2024 | Behind the Markets (Ad)BiomX shares hold Buy rating from H.C. Wainwright on Q3 resultsNovember 17, 2024 | uk.investing.comBiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program UpdatesNovember 14, 2024 | globenewswire.comBiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024November 12, 2024 | globenewswire.comBiomX Announces a Mandatory Unit SeparationOctober 15, 2024 | globenewswire.comBiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis ConferenceSeptember 18, 2024 | globenewswire.comSee More Headlines PHGE Stock Analysis - Frequently Asked Questions How have PHGE shares performed this year? BiomX's stock was trading at $2.80 at the start of the year. Since then, PHGE shares have decreased by 77.9% and is now trading at $0.62. View the best growth stocks for 2024 here. How were BiomX's earnings last quarter? BiomX Inc. (NYSEMKT:PHGE) announced its quarterly earnings results on Monday, May, 15th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.80) by $0.20. When did BiomX's stock split? BiomX's stock reverse split on the morning of Monday, August 26th 2024. The 1-10 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are BiomX's major shareholders? BiomX's top institutional shareholders include Ikarian Capital LLC (4.99%), Johnson & Johnson (1.07%), 8VC GP I LLC (0.61%) and Barclays PLC (0.14%). Insiders that own company stock include Israel Biofund Gp Limi Orbimed, Chidozie Ugwumba and Assaf Oron. View institutional ownership trends. How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some other companies that BiomX investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), NVIDIA (NVDA), Zomedica (ZOM), Insulet (PODD) and Ford Motor (F). Company Calendar Last Earnings5/15/2023Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNYSEMKT:PHGE CUSIPN/A CIK1739174 Webwww.biomx.com Phone972 7 23942377FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$25.00 Low Stock Price Target$20.00 Potential Upside/Downside+3,529.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.82% Return on Assets-56.50% Debt Debt-to-Equity Ratio0.51 Current Ratio2.84 Quick Ratio2.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.89Miscellaneous Outstanding Shares18,177,000Free Float44,044,000Market Cap$11.27 million OptionableNot Optionable Beta1.31 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NYSEMKT:PHGE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BiomX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.